HIV, reproductive aging, and health implications in women: A literature review

Menopause

Volumn 16, Issue 1, 2009, Pages 199-213

  Conde, Délio Marques ^a,d   Silva, Emanuela T ^b   Amaral, Waldemar N ^a   Finotti, Marta F ^a   Ferreira, Rui G ^a   Costa Paiva, Lúcia ^c   Pinto Neto, Aarão M ^c  

^a UFGO Universidade Federal University de Goiás   (Brazil)

^b HOSPITAL GERAL DE FORTALEZA   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d NONE   (Brazil)

Author keywords

Acquired immunodeficiency syndrome; Highly active antiretroviral therapy; Human immunodeficiency virus; Menopausal symptoms; Menopause; Middle age

Indexed keywords

ALENDRONIC ACID; CALCIUM; RITONAVIR; TENOFOVIR; VITAMIN D; ZIDOVUDINE; GLUCOSE; HORMONE;

AGING; BONE DENSITY; CLINICAL TRIAL; COGNITION; GLUCOSE METABOLISM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MENOPAUSAL SYNDROME; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; OSTEOSCLEROSIS; REVIEW; SEXUAL BEHAVIOR; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; MEDLINE; MENOPAUSE; METABOLISM; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; REPRODUCTION;

AGING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; CARDIOVASCULAR DISEASES; COGNITION; FEMALE; GLUCOSE; HIV INFECTIONS; HIV SEROPOSITIVITY; HORMONES; HUMANS; LIPID METABOLISM; MEDLINE; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; REPRODUCTION; SEXUAL BEHAVIOR;

EID: 64049090665     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318177352c     Document Type: Review

References (165)

1. Joint United Nations Programme on HIV/AIDS 2007 AIDS epidemic update. Geneva: UNAIDS; December 2007. Available at: http://data.unaids.org/pub/ EPISlides/2007/2007-epiupdate-en.pdf. Accessed December 10, 2007.
2. Ghosh J, Kalipeni E. Women in Chinsapo, Malawi: vulnerability and risk to HIV/AIDS. SAHARA J 2005;2:320-332.
3. Lin K, McElmurry BJ, Christiansen C. Women and HIV/AIDS in China: gender and vulnerability. Health Care Women Int 2007;28:680-699.
4. Sormanti M, Shibusawa T. Predictors of condom use and HIV testing among midlife and older women seeking medical services. J Aging Health 2007;19:705-719.
5. Centers for Disease Control and Prevention. HIV/AIDS Fact Sheet. HIV/AIDS among women. Available at: http://www.cdc.gov/hiv/resources/factsheets/PDF/ women.pdf. Accessed December 16, 2007.
6. Brazilian Ministry of Health. Epidemiological Bulletin STDs/AIDS-1st to the 26th epidemiological weeks, 2006. Available at: http://www.aids.gov.br/data/ documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/ %7B6B12D137-92DF-4CF5-A35A-482AED64CBC0%7D/BOLETIM2006internet.pdf. Accessed December 20, 2007.
7. Schechter M. Treatment at scale in Brazil: a physician's perspective. AIDS 2007;21(Suppl 4):S31-S35.
8. Hacker MA, Petersen ML, Enriquez M, Bastos FI. Highly active antiretroviral therapy in Brazil: the challenge of universal access in a context of social inequality. Rev Panam Salud Publica 2004;16:78-83.
9. Clark RA, Cohn SE, Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 2000;23:99-100.
10. Fantry LE, Zhan M, Taylor GH, Sill AM, Flaws JA. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS 2005;19:703-711.
11. Ferreira CE, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Magalhaes J. Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol 2007;23:198-205.
12. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005;41:1517-1524.
13. HE Cejtin, S Kim, RN Taylor, et al. Menopause in women in the Women's Interagency HIV Study (WIHS) [abstract WePeD6504]. Bangkok: XV International AIDS Conference, 2004. Available at: http://gateway.nlm.nih.gov/ MeetingAbstracts/102284419.html. Accessed December 1, 2007.
14. Miller SA, Santoro N, Lo Y, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause 2005;12:348-356.
15. Santoro N, Arnsten JH, Buono D, Howard AA, Schoenbaum EE. Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women. J Womens Health (Larchmt) 2005;14:898-905.
16. Cofrancesco J Jr, Shah N, Ghanem KG, et al. The effects of illicit drug use and HIV infection on sex hormone levels in women. Gynecol Endocrinol 2006;22:244-251.
17. Santoro N, Lo Y, Moskaleva G, et al. Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women. Menopause 2007;14:859-865.
18. Richardson JL, Martin EM, Jimenez N, et al. Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy. J Int Neuropsychol Soc 2002;8:781-793.
19. Dolan S, Montagno A, Wilkie S, et al. Neurocognitive function in HIV-infected patients with low weight and weight loss. J Acquir Immune Defic Syndr 2003;34:155-164.
20. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003;46:221-227.
21. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004;18:475-483.
22. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005;16:1345-1352.
23. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006;42:1014-1020.
24. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006;91:2938-2945.
25. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005;39:44-54.
26. Floris-Moore M, Howard AA, Lo Y, Arnsten JH, Santoro N, Schoenbaum EE. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women. HIV Med 2006;7:421-430.
27. Rimland D, Guest JL, Hernandez-Ramos I, Del Rio C, Le NA, Brown WV. Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol. J Acquir Immune Defic Syndr 2006;42:307-313.
28. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007;45:34-42.
29. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003;32:298-302.
30. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005;40:1492-1499.
31. Danoff A, Shi Q, Justman J, et al. Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005;39:55-62.
32. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007;21:1739-1745.
33. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005. Revised June 2007. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2005report/pdf/2005SurveillanceReport.pdf. Accessed December 20, 2007.
34. Brazilian Ministry of Health. Epidemiological Bulletin STDs/AIDS-1st to the 26th epidemiological weeks, 2005. Available at: http://www.aids.gov.br/data/ documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/ %7BED005A42-14BE-4F7E-98A7-E6AD7CD9A76D%7D/BOLETIMpdf. Accessed December 20, 2007.
35. Comision Nacional de SIDA-CONASIDA. Epidemiology of HIV/AIDS in Chile. December 2003. Rev Chilena Infectol 2005;22:169-202.
36. Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/AIDS-United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006;55:589-592.
37. Centers for Disease Control and Prevention. HIV/AIDS Surveillance in Women. Revised June 2007. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/slides/women/slides/Women.pdf. Accessed December 18, 2007.
38. Binson D, Pollack L, Catania JA. AIDS-related risk behaviors and safer sex practices of women in midlife and older in the United States: 1990 to 1992. Health Care Women Int 1997;18:343-354.
39. Ory MG, Mack KA. Middle-aged and older people with AIDS: trends in national surveillance rates, transmission routes, and risk factors. Res Aging 1998;20:653-664.
40. Akers A, Bernstein L, Henderson S, Doyle J, Corbie-Smith G. Factors associated with lack of interest in HIV testing in older at-risk women. J Womens Health (Larchmt) 2007;16:842-858.
41. Henderson SJ, Bernstein LB, St. George DM, Doyle JP, Paranjape AS, Corbie-Smith G. Older women and HIV: how much do they know and where are they getting their information? J Am Geriatr Soc 2004;52:1549-1553.
42. Winningham A, Corwin S, Moore C, Richter D, Sargent R, Gore-Felton C. The changing age of HIV: sexual risk among older African American women living in rural communities. Prev Med 2004;39:809-814.
43. Gott M, Hinchliff S. Barriers to seeking treatment for sexual problems in primary care: a qualitative study with older people. Fam Pract 2003;20:690-695.
44. Paranjape A, Bernstein L, St. George DM, Doyle J, Henderson S, Corbie-Smith G. Effect of relationship factors on safer sex decisions in older inner-city women. J Womens Health (Larchmt) 2006;15:90-97.
45. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-874.
46. Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005;162:1089-1097.
47. Parazzini F. Progetto Menopause Italia Study Group. Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas 2007;56:280-287.
48. Castelo-Branco C, Blümel JE, Chedraui P, et al. Age at menopause in Latin America. Menopause 2006;13:706-712.
49. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab 1998;83:1875-1880.
50. Pedro AO, Pinto-Neto AM, Paiva LH, Osis MJ, Hardy E. Age at natural menopause among Brazilian women: results from a population-based survey. Cad Saude Publica 2003;19:17-25.
51. Fallahzadeh H. Age at natural menopause in Yazd, Islamic Republic of Iran. Menopause 2007;14:900-904.
52. Cejtin HE, Kalinowski A, Bacchetti P, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 2006;108:1423-1431.
53. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-878.
54. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003;14:525-530.
55. van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 2004;19:1172-1180.
56. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066.
57. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005;16:556-562.
58. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
59. Conde DM, Pinto-Neto AM, Costa-Paiva L Age at menopause of HIV-infected women: a review. Gynecol Endocrinol 2008;24:84-86.
60. Conde DM, Pinto-Neto AM, Santos-Sa D, Costa-Paiva L, Martinez EZ. Factors associated with quality of life in a cohort of postmenopausal women. Gynecol Endocrinol 2006;22:441-446.
61. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473.
62. Fuh JL, Wang SJ, Lee SJ, Lu SR, Juang KD. Quality of life and menopausal transition for middle-aged women on Kinmen Island. Qual Life Res 2003;12:53-61.
63. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31.
64. North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-182.
65. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007;186:146-151.
66. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 2007;3:583-598.
67. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
68. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:568-575.
69. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
70. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-166.
71. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-793.
72. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-824.
73. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
74. Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 2006;5:83-87.
75. Muttukrishna S, Child T, Lockwood GM, Groome NP, Barlow DH, Ledger WL. Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women. Hum Reprod 2000;15:549-556.
76. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-275.
77. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 2007;13:559-565.
78. Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;88:1516-1522.
79. Randolph JF Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004;89:1555-1561.
80. Aloysi A, Van Dyk K, Sano M. Women's cognitive and affective health and neuropsychiatry. Mt Sinai J Med 2006;73:967-975.
81. Elsabagh S, Hartley DE, File SE. Cognitive function in late versus early postmenopausal stage. Maturitas 2007;56:84-93.
82. Craig MC, Murphy DG. Oestrogen, cognition and the maturing female brain. J Neuroendocrinol 2007;19:1-6.
83. Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update 2007;13:175-187.
84. Bottino CMC, Cid CG, Camargo CHP. Avaliação Neuropsicolo gica. In: Forlenza OV, Almeida OP eds. Depressão e Demência no Idoso-Tratamento Psicolo gico e Farmacologico. São Paulo: Lemos Editorial, 1997:121-140.
85. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003;9:205-221.
86. Vázquez-Justo E, Rodríguez-Alvarez M. Influence of factors not related with HIV infection on neuropsychological performance of HIV-seropositive patients. Rev Neurol 2002;35:474-480.
87. Casanova-Sotolongo P, Casanova-Carrillo P, Casanova-Carrillo C. Dementia associated with AIDS. Rev Neurol 2002;34:781-787.
88. Morrison MF, Petitto JM, Ten Have T, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002;159:789-796.
89. Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr 2002;30:401-409.
90. Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, Smith D. Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 1999;13:2459-2468.
91. Mello VA, Malbergier A. Depression in women infected with HIV. Rev Bras Psiquiatr 2006;28:10-17.
92. Ickovics JR, Hamburger ME, Vlahov D, et al, HIV Epidemiology Research Study Group. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285:1466-1474.
93. Woods SP, Carey CL, Moran LM, Dawson MS, Letendre SL. Grant I; HIV Neurobehavioral Research Center (HNRC) Group. Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Arch Clin Neuropsychol 2007;22:187-195.
94. Rabkin JG, Ferrando SJ, van Gorp W, Rieppi R, McElhiney M, Sewell M. Relationships among apathy, depression, and cognitive impairment in HIV/AIDS. J Neuropsychiatry Clin Neurosci 2000;12:451-457.
95. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004;45:394-402.
96. Starace F, Bartoli L, Aloisi MS, et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002;106:20-26.
97. De Ronchi D, Faranca I, Berardi D, et al. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Arch Neurol 2002;59:812-818.
98. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005;4:543-555.
99. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004;61:1687-1696.
100. Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 2004;18(Suppl 1):S79-S86.
101. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004;157:3-10.
102. Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis 2006;42:1449-1454.
103. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ, National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003;17:1539-1545.
104. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921.
105. McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007;21:1109-1117.
106. Schifitto G, Kieburtz K, McDermott MP, et al. Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001;56:415-418.
107. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
108. Wojna V, Skolasky RL, Hechavarria R, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 2006;12:356-364.
109. Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci 2005;32:201-204.
110. Osowiecki DM, Cohen RA, Morrow KM, et al. Neurocognitive and psychological contributions to quality of life in HIV-1-infected women. AIDS 2000;14:1327-1332.
111. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10:317-331.
112. Cohen RA, Boland R, Paul R, et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS 2001;15:341-345.
113. Fillit HM, Butler RN, O'Connell AW, et al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc 2002;77:681-696.
114. Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev 2006;30:730-748.
115. Prior J, Burdge D, Maan E, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007;18:1345-1353.
116. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822.
117. Costa-Paiva L, Horovitz AP, Santos AO, Fonsechi-Carvasan GA, Pinto-Neto AM. Prevalence of osteoporosis in postmenopausal women and association with clinical and reproductive factors. Rev Bras Ginecol Obstet 2003;25:507-512.
118. Shilbayeh S. Prevalence of osteoporosis and its reproductive risk factors among Jordanian women: a cross-sectional study. Osteoporos Int 2003;14:929-940.
119. Yang TS, Chen YR, Chen YJ, Chang CY, Ng HT. Osteoporosis: prevalence in Taiwanese women. Osteoporos Int 2004;15:345-347.
120. Baheiraei A, Pocock NA, Eisman JA, Nguyen ND, Nguyen TV. Bone mineral density, body mass index and cigarette smoking among Iranian women: implications for prevention. BMC Musculoskelet Disord 2005;6:34.
121. National Osteoporosis Foundation. NOF Patient info-medications to prevent and treat osteoporosis. Available at: http://www.nof.org/patientinfo/ medications.htm#Bone%20Remodeling%20Cycle. Accessed December 20, 2007.
122. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006;42:108-114.
123. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk. J Biol Chem 2003;278:48251-48258.
124. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-κB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005;150:67-78.
125. Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses 2004;20:608-620.
126. MW Wang, SL Teitelbaum, P Tebas, WG Powderly, FP Ross, Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function [abstract 541]. Chicago, IL: 8th Conference on Retroviruses and Opportunistic Infections, 2001. Available at: http://www.retroconference.org/2001/Abstracts/ Abstracts/Abstracts/541.htm. Accessed December 1, 2007.
127. Khosla S, Melton LJ 3rd, Atkinson EJ, Fallon O'WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274.
128. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17:1917-1923.
129. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-2174.
130. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)-propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004;48:1469-1487.
131. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001;15:1275-1280.
132. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004;114:206-213.
133. JM Fakruddin, M Yin, J Laurence, Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy [abstract 822]. Boston, MA: 12th Conference on Retroviruses and Opportunistic Infections, 2005. Available at: http://www.retroconference.org/2005/cd/Abstracts/24609.htm. Accessed December 1, 2007.
134. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999;84:145-150.
135. Anastos K, Lu D, Shi O, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther 2007;12:1049-1058.
136. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia-osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38:426-431.
137. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005;19:343-345.
138. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia-osteoporosis. HIV Clin Trials 2004;5:269-277.
139. Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev 2007;(2):CD005645.
140. Negredo E, Martinez E, Cinquegrana D, Estany C, Clotet B. Therapeutic management of bone demineralization in the HIV-infected population. AIDS 2007;21:657-663.
141. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
142. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-1193.
143. Mondy K, Tebas P. Cardiovascular risks of antiretroviral therapies. Annu Rev Med 2007;58:141-155.
144. Gharakhanian S, Salhi Y, Nguyen TH, et al. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors [abstract 642]. Chicago, IL: 6th Conference on Retroviruses and Opportunistic Infections, 1999. Available at: http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102195407.html. Accessed August 13, 2008.
145. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999;84:1932-1937.
146. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003;34:461-466.
147. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-471.
148. Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai 2004;87:605-611.
149. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999;21:107-113.
150. Martinez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-598.
151. Huang JS, Harrity S, Lee D, Becerra K, Santos R, Mathews WC. Body image in women with HIV: a cross-sectional evaluation. AIDS Res Ther 2006;3:17.
152. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002;3:49-55.
153. Poehlman ET, Toth MJ, Ades PA, Rosen CJ. Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. Eur J Clin Invest 1997;27:322-326.
154. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-298.
155. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 2001;32:1104-1111.
156. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
157. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
158. FJ Torriani, RA Parker, RL Murphy, et al. Antiretroviral therapy improves endothelial function in treatment-naïve HIV-infected subjects: a prospective, randomized multicenter trial [PS5/3]. Dublin, Ireland: 10th European AIDS Conference, 2005. Available at: http://www.eacs.eu/conference/ dublin05/RES/214.html. Accessed August 13, 2008.
159. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-933.
160. Johnsen S, Dolan SE, Fitch KV, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4916-4924.
161. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation 1996;94:61-66.
162. Otsuki M, Kasayama S, Morita S, et al. Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause 2007;14:404-407.
163. Currier JS. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002;31(Suppl 1):S16-S23.
164. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007;28:2028-2040.
165. Carosi G, Quiros-Roldan E, Torti C, et al. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). Infection 2007;35:134-142.